University of Michigan

Kura Oncology, Inc.

Hongzhi Miao

Jolanta Grembecka

Tomasz Cierpicki

Szymon Klossowski

EunGi Kim

Jing Deng

Hao Li

Trupta Purohit

Dong Chen

Yi Liu

Pingda Ren

Liansheng Li

Tao Wu

Jun Feng

Duxin Sun

Dmitry Borkin

Jonathan Pollock

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

ASH1L degraders and methods of treatment therewith

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

ASH1L inhibitors and methods of treatment therewith

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

Thienopyrimidine and thienopyridine compounds and methods of use thereof

Growing community of inventors

Ann Arbor, MI, United States of America

Hongzhi Miao